Literature DB >> 1324586

GABAA-receptor subtypes differing in alpha-subunit composition display unique pharmacological properties.

H Mohler1, D Benke, S Mertens, J M Fritschy.   

Abstract

GABAA-receptor subtypes in rat brain were characterized using anti-peptide antisera specific for the alpha 1-, alpha 3- and alpha 5-subunits. While a high abundance of alpha 1-containing receptors was demonstrated by immunoprecipitation (80-90% of receptors), the receptors precipitated with the alpha 3- and the alpha 5-antiserum were less frequent (18-25% and 10-23%, respectively). The three receptor populations displayed unique pharmacological properties as shown by radioligand binding. Diazepam, flumazenil and flunitrazepam displayed similar displacing potencies in [3H]-flumazenil binding. However, the affinities of CL 218872, beta CCM and zolpidem were up to 10-fold lower in the alpha 3- than the alpha 1-receptor population while intermediate values were found for the alpha 5-receptor population. In many brain areas, a neuron-specific expression of receptors containing either alpha 1- or alpha 3-subunits could be visualized immunohistochemically. It will be of major interest to determine, whether ligands with differential affinities for receptor subtypes in situ will provide novel therapeutic profiles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324586

Source DB:  PubMed          Journal:  Adv Biochem Psychopharmacol        ISSN: 0065-2229


  10 in total

1.  In vivo evidence of the specificity of effects of GABA(A) receptor modulating medications.

Authors:  Andrew D Krystal
Journal:  Sleep       Date:  2010-07       Impact factor: 5.849

2.  GABAA Receptors of Cerebellar Granule Cells in Culture: Interaction with Benzodiazepines.

Authors:  Aroldo Cupello; Mario Di Braccio; Elena Gatta; Giancarlo Grossi; Periklis Nikas; Francesca Pellistri; Mauro Robello
Journal:  Neurochem Res       Date:  2013-10-12       Impact factor: 3.996

3.  Critical period for inhibitory plasticity in rodent binocular V1.

Authors:  Arianna Maffei; Mary E Lambo; Gina G Turrigiano
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

4.  Alterations in t-butylbicyclophosphorothionate binding in the brains of lidocaine-kindled rats.

Authors:  M S Abel; D E Carney
Journal:  Metab Brain Dis       Date:  1993-12       Impact factor: 3.584

5.  Neural bases for addictive properties of benzodiazepines.

Authors:  Kelly R Tan; Matthew Brown; Gwenaël Labouèbe; Cédric Yvon; Cyril Creton; Jean-Marc Fritschy; Uwe Rudolph; Christian Lüscher
Journal:  Nature       Date:  2010-02-11       Impact factor: 49.962

6.  Alcohol-induced tolerance and physical dependence in mice with ethanol insensitive alpha1 GABA A receptors.

Authors:  David F Werner; Andrew R Swihart; Carolyn Ferguson; William R Lariviere; Neil L Harrison; Gregg E Homanics
Journal:  Alcohol Clin Exp Res       Date:  2008-11-19       Impact factor: 3.455

Review 7.  Regulating the Efficacy of Inhibition Through Trafficking of γ-Aminobutyric Acid Type A Receptors.

Authors:  Thuy N Vien; Stephen J Moss; Paul A Davies
Journal:  Anesth Analg       Date:  2016-11       Impact factor: 5.108

8.  GABA(A) receptors in normal development and seizures: friends or foes?

Authors:  Aristea S Galanopoulou
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

Review 9.  Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.

Authors:  Antonio Daniele; Francesco Panza; Antonio Greco; Giancarlo Logroscino; Davide Seripa
Journal:  Parkinsons Dis       Date:  2016-05-17

10.  Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors.

Authors:  William T Ralvenius; Elena Neumann; Martina Pagani; Mario A Acuña; Hendrik Wildner; Dietmar Benke; Nina Fischer; Ana Rostaher; Simon Schwager; Michael Detmar; Katrin Frauenknecht; Adriano Aguzzi; Jed Lee Hubbs; Uwe Rudolph; Claude Favrot; Hanns Ulrich Zeilhofer
Journal:  Nat Commun       Date:  2018-08-13       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.